Highly sensitive assessment of neuroblastoma minimal residual disease in ovarian tissue using RT‐qPCR—A strategy for improving the safety of fertility restoration

Grèze, Victoria; Brugnon, Florence; Chambon, F.; Hallé, Pierre; Canis, Michel; Amiot, Clotilde; Grémeau, Anne-Sophie; Pereira, Bruno; Yáñez, Yania; Tchirkov, Andréï; Kanold, Justyna

doi:10.1002/pbc.26287

Cited by 13 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these circumstances, patients are at risk of primary disease recurrence upon transplantation of ovarian tissue. In a study by Greze et al (2017), healthy ovarian tissue from 20 patients was in vitro contaminated with human NB cell lines and subsequently tested for minimal residual disease (MRD) with RT-qPCR for the relevant genes. The results showed PHOX2B (paired-like homeobox 2b) to be a reliable and sensitive marker of NB cells contaminating ovarian tissue, as it was able to detect as few as ten neoplastic cells present in the ovarian fragments.…”

Section: Neuroblastomamentioning

confidence: 99%

“…The results showed PHOX2B (paired-like homeobox 2b) to be a reliable and sensitive marker of NB cells contaminating ovarian tissue, as it was able to detect as few as ten neoplastic cells present in the ovarian fragments. Cryopreserved ovarian tissue from two prepubertal patients with NB was also tested, but the PHOX2B gene was not detected by RT-qPCR, suggesting an absence of NB cells in these samples (Greze et al 2017).…”

Section: Neuroblastomamentioning

confidence: 99%

See 1 more Smart Citation

FERTILITY PRESERVATION: Construction and use of artificial ovaries

Dolmans

Amorim

2019

Reproduction

View full text Add to dashboard Cite

Increasing numbers of patients are now surviving previously fatal malignant diseases, so for women of childbearing age, fertility concerns are paramount once they are cured. However, the treatments themselves, namely chemo- and radiotherapy, can cause considerable damage to endocrine and reproductive functions, often leaving these women unable to conceive. When such gonadotoxic therapy cannot be postponed due to the severity of the disease or for prepubertal girls, the only way to preserve fertility is cryobanking their ovarian tissue for future use. Unfortunately, with some types of cancer, there is a risk of reimplanting malignant cells together with the frozen-thawed tissue, so it is not recommended. A safer approach involves grafting isolated preantral follicles back to their native environment inside a specially created transplantable artificial ovary for their protection. This bioengineered ovary must mimic the natural organ and therefore requires an appropriate scaffold to encapsulate not only isolated follicles, but also autologous ovarian cells, which are needed for follicles to survive and develop. Here we review the indications for use of this artificial ovary and advances in the field that are bringing us ever closer to clinical implementation.

show abstract

Section: Neuroblastomamentioning

confidence: 99%

Section: Neuroblastomamentioning

confidence: 99%

FERTILITY PRESERVATION: Construction and use of artificial ovaries

Dolmans

Amorim

2019

Reproduction

View full text Add to dashboard Cite

show abstract

“…In addition, recent mapping of the neuroblastoma super-enhancer landscape demonstrated that a subset of neuroblastoma cells with adrenergic properties express PHOX2B , and that PHOX2B knockdown impairs these cells’ growth(Boeva et al 2017; van Groningen et al 2017). In clinical practice, PHOX2B positivity via immunohistochemistry can help distinguish neuroblastomas from other small round blue cell tumors, and PHOX2B mRNA expression offers a promising biomarker for the detection of minimal residual disease (Hung et al 2017; Greze, Brugnon, et al 2017; Greze, Kanold, et al 2017). However, given recent insights into the heterogeneity of cell types and differentiation states present within a given tumor, the absence of PHOX2B expression may not definitively exclude the presence of neuroblastoma.…”

Section: Familial Neuroblastomamentioning

confidence: 99%

Genetic susceptibility to neuroblastoma: current knowledge and future directions

et al. 2018

View full text Add to dashboard Cite

Neuroblastoma, a malignancy of the developing peripheral nervous system that affects infants and young children, is a complex genetic disease. Over the past two decades, significant progress has been made toward understanding the genetic determinants that predispose to this often lethal childhood cancer. Approximately 1-2% of neuroblastomas are inherited in an autosomal dominant fashion and a combination of co-morbidity and linkage studies has led to the identification of germline mutations in PHOX2B and ALK as the major genetic contributors to this familial neuroblastoma subset. The genetic basis of "sporadic" neuroblastoma is being studied through a large genome-wide association study (GWAS). These efforts have led to the discovery of many common susceptibility alleles, each with modest effect size, associated with the development and progression of sporadic neuroblastoma. More recently, next-generation sequencing efforts have expanded the list of potential neuroblastoma-predisposing mutations to include rare germline variants with a predicted larger effect size. The evolving characterization of neuroblastoma's genetic basis has led to a deeper understanding of the molecular events driving tumorigenesis, more precise risk stratification and prognostics and novel therapeutic strategies. This review details the contemporary understanding of neuroblastoma's genetic predisposition, including recent advances and discusses ongoing efforts to address gaps in our knowledge regarding this malignancy's complex genetic underpinnings.

show abstract

“…One of several significant issues in ovarian tissue preservation is the risk of reseeding malignant cells that may cause reoccurrence of primary cancer [41]. A high risk of malignant cell reimplantation has been primarily observed in hematological malignancies [10,79,80], such as leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma [11]. Ovarian metastases have been additionally observed in gastric cancer (55.8%), colon cancer (26.6%), and lung cancer (23.4%) [81].…”

Section: Ovarian Tissue Cryopreservation and Reimplantationmentioning

confidence: 99%

Fertility-sparing in cancer patients

Karakaş¹,

Kaya²,

Schäfer³

et al. 2021

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

This review aimed to investigate and summarize the current evidence on fertility-sparing options in cancer patients. Mechanism: Fertility preservation methods are becoming popular through the improved prognosis of cancer patients at a younger age and early diagnostic tools. However, currently, more and more women are suffering from iatrogenic ovarian failure and fertility loss because of cancer treatment. Most treatments have been used for hematological malignancies, but different gynecological cancers can be eligible. Findings in brief : Fertility preserving strategies such as oocyte and embryo cryopreservation, ovarian tissue preservation, ovarian transposition, and aspiration of ovarian follicles are the methods that could be suggested to the patients. The current knowledge supports oocyte and embryo cryopreservation as feasible, safe, and effective treatment approaches for cancer patients seeking fertility preservation. Conclusions: Robust evidence is still needed to prove the effectiveness of cryopreservation of the ovarian tissue and ovarian follicle aspiration approaches since these techniques are still in early their steps.

show abstract

Highly sensitive assessment of neuroblastoma minimal residual disease in ovarian tissue using RT‐qPCR—A strategy for improving the safety of fertility restoration

Abstract: These results are encouraging and offer hope in the near future for grafting ovarian tissue in women who survive cancer, whose fertility has been jeopardized by treatment, and who could benefit from OTC without oncological risk.

Cited by 13 publications

References 36 publications

FERTILITY PRESERVATION: Construction and use of artificial ovaries

FERTILITY PRESERVATION: Construction and use of artificial ovaries

Genetic susceptibility to neuroblastoma: current knowledge and future directions

Fertility-sparing in cancer patients

Contact Info

Product

Resources

About